Beyond Single Antigen B Cell Depletion: CD19/BCMA Dual Targeting T-Cell Engagers for Durable Immune Reset in Autoimmune Disease
- Achieving deeper, more complete disease control by dual targeting of CD19 and BCMA to deplete the full spectrum of pathological B cells driving autoimmunity
- Maximizing therapeutic window and clinical potential through tri specific TCE engineering that balances potency and safety across CD19, BCMA and CD3
- Accelerating translation into the clinic by positioning dual targeting TCEs as a differentiated path toward durable immune reset in severe autoimmune disease